PPARα Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes
Authors:
Open Access
- 1 June 2007
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 56 (6) , 1662-1670
Abstract
Osteopontin (OPN) is a proinflammatory cytokine implicated in the chemoattraction of monocytes and the development of atherosclerosis. Peroxisome proliferator–activated receptor (PPAR)α, a ligand-activated transcription factor with pleiotropic anti-inflammatory effects in macrophages, is the molecular target for fibrates, which are frequently used to treat dyslipidemia in patients with type 2 diabetes at high risk for cardiovascular disease. In the present study, we examined the regulation of OPN by PPARα agonists in macrophages and determined the effect of fibrate treatment on OPN plasma levels in patients with type 2 diabetes. Treatment of human macrophages with the PPARα ligands bezafibrate or WY14643 inhibited OPN expression. PPARα ligands suppressed OPN promoter activity, and an activator protein (AP)-1 consensus site conferred this repression. Overexpression of c-Fos and c-Jun reversed the inhibitory effect of PPARα ligands on OPN transcription, and, in chromatin immunoprecipitation assays, PPARα ligands inhibited c-Fos and phospho–c-Jun binding to the OPN promoter. Moreover, c-Fos and phospho–c-Jun protein expression was inhibited by PPARα agonists, indicating that PPARα ligands suppress OPN expression through negative cross talk with AP-1–dependent transactivation of the OPN promoter. This inhibitory effect of PPARα ligands on OPN expression was absent in PPARα-deficient macrophages, suggesting a receptor-mediated mechanism of OPN suppression. Finally, treatment of type 2 diabetic patients with bezafibrate significantly decreased OPN plasma levels. These results demonstrate a novel mechanism whereby PPARα ligands may impact macrophage inflammatory responses and decrease early proinflammatory markers for cardiovascular disease.Keywords
This publication has 34 references indexed in Scilit:
- Inflammation and insulin resistanceJournal of Clinical Investigation, 2006
- Insulin resistance and atherosclerosisJournal of Clinical Investigation, 2006
- Prognostic significance of plasma osteopontin levels in patients with chronic stable anginaEuropean Heart Journal, 2006
- Peroxisome Proliferator–Activated Receptor α Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR-α Activation PropertiesCirculation Research, 2004
- Peroxisome Proliferator-Activated Receptors and AtherogenesisCirculation Research, 2004
- Endothelin-1–Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator–Activated Receptor-α Partly Via Blockade of c-Jun NH 2 -Terminal Kinase PathwayCirculation, 2004
- PPARγ Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 CellsCirculation Research, 2002
- Enhanced Expression of Osteopontin by High Glucose: Involvement of Osteopontin in Diabetic MacroangiopathyaAnnals of the New York Academy of Sciences, 2000
- Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived MacrophagesJournal of Biological Chemistry, 1998
- Angiotensin II Induction of Osteopontin Expression and DNA Replication in Rat ArteriesHypertension, 1996